Back
ghfus | 20809

Myeloid fusion transcripts

Keywords:
ABL1
ALK
Acute leukaemia
BCL2
BRAF
CCND1
CREBBP
EGFR
ETV6
FGFR1
FGFR2
FUS
HMGA2
JAK2
KMT2A (MLL)
MDS
MECOM
MET
MLLT10
MLLT3
MYBL1
MYH11
Myelodisplastic syndrome
Myelodysplastic neoplasms
NTRK3
NUP214
PDGFRA
PDGFRB
RARA
RBM15
RUNX1
TCF3
TFE3
fusions

Status

Material
Bone marrow blood EDTA-Tube bone marrow (6)
Hint
Fusionen mit den folgenden 29 Genen: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A (MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3 | This analysis can be ordered by phone, after consultation with the consultation team, from bone marrow (stability 2 days) or asserved RNA. | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. | Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent).
Stability
Stability
1 day / 2-8°C; 2 years / -20°C
Duration 3 days
Frequency 2 x per week
Method Next Generation Sequencing

Price/Rate

Price
Price
CHF 954.90
Rate
Rate
954.90 TP